| SYY |
Report |
Adjusted EPS (2026Q4) |
IN-LINE |
pred ~$1.52 vs. cons $1.51 |
HIGH |
| SYY |
Report |
Revenue (2026Q4) |
IN-LINE |
pred ~$21.95B vs. cons $21.90B |
MEDIUM |
| SYY |
Report |
U.S. local case growth (2026Q4) |
BEAT |
pred ~2.8% vs. cons 2.5% |
MEDIUM |
| SYY |
Guide |
Adjusted EPS guidance |
LOWER |
guide ~$4.88 vs. cons $5.01 (FY2027) |
MEDIUM |
| SYY |
Guide |
Revenue guidance |
LOWER |
guide ~$88.0B vs. cons $88.5B (FY2027) |
MEDIUM |
| SYY |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.4% |
— |
MEDIUM |
| SYY |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
A largely in-line quarter and local-volume beat are outweighed by FY2027 guidance below consensus; the ~$0.13 EPS and ~$0.5B revenue shortfalls imply negative out-period revisions that continue after day 1. |
MEDIUM |